ID

38227

Description

The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01996410

Link

https://clinicaltrials.gov/show/NCT01996410

Keywords

Versions (1)
  1. 9/29/19 9/29/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 29, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer Stages I Through III NCT01996410

English

Eligibility Breast Cancer Stages I Through III NCT01996410

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
18 years or older
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
english speaking/reading/writing
Description

Able to speak English Language | Able to read English Language | Able to write English Language

Data type

boolean

Alias
UMLS CUI [1,1]
C0564215
UMLS CUI [1,2]
C0376245
UMLS CUI [2,1]
C0586740
UMLS CUI [2,2]
C0376245
UMLS CUI [3,1]
C0584993
UMLS CUI [3,2]
C0376245
breast cancer stages i through iii
Description

Breast Carcinoma TNM Breast tumor staging

Data type

boolean

Alias
UMLS CUI [1,1]
C0678222
UMLS CUI [1,2]
C0474926
any performance status suitable for chemotherapy as determined by the physician
Description

Performance status Suitable Chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C1518965
UMLS CUI [1,2]
C3900053
UMLS CUI [1,3]
C0392920
primary or secondary chemotherapy, but enrolling patients prior to a chemotherapy regimen regardless of previous radiation therapy exposure and/or previous mastectomy.
Description

Chemotherapy Primary | Chemotherapy Secondary

Data type

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0205225
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0175668
scheduled to receive either of the following two regimens:
Description

Regimen Scheduled

Data type

boolean

Alias
UMLS CUI [1,1]
C0040808
UMLS CUI [1,2]
C0205539
adriamycin (60 mg/m2), cytoxan (600 mg/m2), taxol (175 mg/m2)
Description

Adriamycin Dosage | Cytoxan Dosage | Taxol Dosage

Data type

boolean

Alias
UMLS CUI [1,1]
C0085752
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0699319
UMLS CUI [2,2]
C0178602
UMLS CUI [3,1]
C0678133
UMLS CUI [3,2]
C0178602
adriamycin (60 mg/m2), cytoxan (600 mg/m2), taxol (80 g/m2)
Description

Adriamycin Dosage | Cytoxan Dosage | Taxol Dosage

Data type

boolean

Alias
UMLS CUI [1,1]
C0085752
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0699319
UMLS CUI [2,2]
C0178602
UMLS CUI [3,1]
C0678133
UMLS CUI [3,2]
C0178602
taxotere (75mg/m2), cytoxan (600 mg/m2)
Description

Taxotere Dosage | Cytoxan Dosage

Data type

boolean

Alias
UMLS CUI [1,1]
C0699967
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0699319
UMLS CUI [2,2]
C0178602
taxotere (75 mg/m2), carboplatin (auc 6), perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose)
Description

Taxotere Dosage | Carboplatin AUC | Perjeta Dosage

Data type

boolean

Alias
UMLS CUI [1,1]
C0699967
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0079083
UMLS CUI [2,2]
C0376690
UMLS CUI [3,1]
C3473371
UMLS CUI [3,2]
C0178602
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of narcolepsy
Description

Narcolepsy

Data type

boolean

Alias
UMLS CUI [1]
C0027404
sleep apnea requiring cpap
Description

Sleep Apnea Requirement CPAP

Data type

boolean

Alias
UMLS CUI [1,1]
C0037315
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0199451
other acupuncture treatment within one month of enrollment
Description

Acupuncture

Data type

boolean

Alias
UMLS CUI [1]
C0394664
acupuncture treatment for chemotherapy in the past
Description

Acupuncture Associated with Chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0394664
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0392920
current participation in any other research studies
Description

Study Subject Participation Status | Research study

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0681814
Back to the top of the page

Similar models

Eligibility Breast Cancer Stages I Through III NCT01996410

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
18 years or older
boolean
C0001779 (UMLS CUI [1])
Able to speak English Language | Able to read English Language | Able to write English Language
Item
english speaking/reading/writing
boolean
C0564215 (UMLS CUI [1,1])
C0376245 (UMLS CUI [1,2])
C0586740 (UMLS CUI [2,1])
C0376245 (UMLS CUI [2,2])
C0584993 (UMLS CUI [3,1])
C0376245 (UMLS CUI [3,2])
Breast Carcinoma TNM Breast tumor staging
Item
breast cancer stages i through iii
boolean
C0678222 (UMLS CUI [1,1])
C0474926 (UMLS CUI [1,2])
Performance status Suitable Chemotherapy
Item
any performance status suitable for chemotherapy as determined by the physician
boolean
C1518965 (UMLS CUI [1,1])
C3900053 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
Chemotherapy Primary | Chemotherapy Secondary
Item
primary or secondary chemotherapy, but enrolling patients prior to a chemotherapy regimen regardless of previous radiation therapy exposure and/or previous mastectomy.
boolean
C0392920 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0175668 (UMLS CUI [2,2])
Regimen Scheduled
Item
scheduled to receive either of the following two regimens:
boolean
C0040808 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
Adriamycin Dosage | Cytoxan Dosage | Taxol Dosage
Item
adriamycin (60 mg/m2), cytoxan (600 mg/m2), taxol (175 mg/m2)
boolean
C0085752 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0699319 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0678133 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
Adriamycin Dosage | Cytoxan Dosage | Taxol Dosage
Item
adriamycin (60 mg/m2), cytoxan (600 mg/m2), taxol (80 g/m2)
boolean
C0085752 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0699319 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0678133 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
Taxotere Dosage | Cytoxan Dosage
Item
taxotere (75mg/m2), cytoxan (600 mg/m2)
boolean
C0699967 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0699319 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
Taxotere Dosage | Carboplatin AUC | Perjeta Dosage
Item
taxotere (75 mg/m2), carboplatin (auc 6), perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose)
boolean
C0699967 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0079083 (UMLS CUI [2,1])
C0376690 (UMLS CUI [2,2])
C3473371 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Narcolepsy
Item
history of narcolepsy
boolean
C0027404 (UMLS CUI [1])
Sleep Apnea Requirement CPAP
Item
sleep apnea requiring cpap
boolean
C0037315 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0199451 (UMLS CUI [1,3])
Acupuncture
Item
other acupuncture treatment within one month of enrollment
boolean
C0394664 (UMLS CUI [1])
Acupuncture Associated with Chemotherapy
Item
acupuncture treatment for chemotherapy in the past
boolean
C0394664 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
Study Subject Participation Status | Research study
Item
current participation in any other research studies
boolean
C2348568 (UMLS CUI [1])
C0681814 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial